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Purpose of the review: More than 50 % of all gynaecological cancers can be classified as rare tumours 
(defined as an annual incidence of < 6 per 100,000) and such tumours represent an important challenge for 
clinicians.  
Recent findings: Rare cancers account for more than one fifth of all new cancer diagnoses, more than any of 
the single common cancers alone. Reviewing the RARECAREnet database, some of the tumours occur 
infrequently, whilst others because of their natural history have a high prevalence, and therefore appear to 
be more common, although their incidence is also rare.  Harmonization of medical practice, guidelines and 
novel trials are needed to identify rare tumours and facilitate the development of new treatments. Ovarian 
tumours are the focus of this review, but we comment on other rare gynaecological tumours, as the diagnosis 
and treatment challenges faced are similar. 
Future: This requires European collaboration, international partnerships, harmonization of treatment and 
collaboration to overcome the regulatory barriers to conduct international trials. Whilst randomized trials 
can be done in many tumour types, there are some for which conducting even single arm studies may be 
challenging. For these tumours alternative study designs, robust collection of data through national registries 
and audits could lead to improvements in the treatment of rare tumours. In addition, concentring the care 
of patients with rare tumours into a limited number of centres will help to build expertise, facilitate trials and 
improve outcomes. 
Introduction 
Until recently the three most common types of gynaecological cancer (epithelial ovarian, cervical and uterine 
tumours) have been managed as individual entities and few adjustments have been made for histological 
subtype(1). The term ‘rare tumour’ referred mostly to non-epithelial subtypes. However, it is now clear that 
different histologic epithelial subtypes of ovarian, endometrial and cervical cancers, have distinct 
pathological behaviour patterns that place many more of these tumours into a ‘rare’ category, defined as an 
annual incidence of ≤ 6 per 100,000 (www. Rarecare.net.eu). Within these subtypes, it is often difficult to 
define clearly the natural history, prognostic factors as well as a definitive histological diagnosis in some of 
these tumours because they are so rare (2;3).  
Defining a clear treatment strategy is often difficult as there is often considerable variability in age, histology, 
pattern of distribution and stage(4). As it has not been feasible to conduct large-scale randomized trials in 
these rare gynaecologic cancers, treatments have generally been developed based on expert opinion or by 
drawing on experience from either more common types of gynaecological cancers, or from other tumours 
with some pathologic similarities. This weak knowledge-based approach means that it is difficult to evaluate 
new cancer therapies in these rare tumours or apply the therapeutic advances made in treating other 
tumours. As a consequence, clinical or  biological research  and management with surgery, radiotherapy and 
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systemic treatment is frequently not optimal(5;6). In this review we focus on rare ovarian tumours, but the 
challenges we face with these tumours are common to other gynaeological tumours, and we include these 
in the discussion of opportunities to overcome current barriers to improving diagnosis, treatment and 
research. 
Challenges 
Epidemiology (table 1) 
RARECAREnet is a 3-year project co-funded by the European Commission (EC), which started in 2012 and 
contributed among other projects to the creation of networks of action for rare diseases. The Fondazione 
IRCCS Istituto Nazionale dei Tumori (Milan, Italy) was the leading organization and more than 20 European 
Institutions and Organizations participate in the project as associated or collaborating partners. The 
RARECAREnet database was drawn from the dataset of EUROCARE-5, the wider collaborative study on cancer 
patients’ survival in Europe (www.eurocare.it). Overall 94 European population-based cancer registries (CRs) 
participating in EUROCARE-5 adhered also to the RARECAREnet project. They provided information on cancer 
patients diagnosed up to 2007 and followed-up for outcomes to the end of 2008 or later. Overall, 27 countries 
were represented in the project, and among them:  
 19 countries were covered by national CRs (Austria, Bulgaria, Czech Republic, Croatia, Estonia, 
England, Finland, Iceland, Northern Ireland, Latvia, Lithuania, Malta, Norway, Republic of Ireland, 
Slovakia, Slovenia, Scotland, The Netherlands, Wales);  
 8 countries were covered by regional CRs partially representing the population of their country 
(Belgium, France, Germany, Switzerland, Italy, Portugal, Poland, and Spain).  
The mean European population covered, over the period 2000-2007, was about 207,942,000, corresponding 
to 48% of the population of countries participating in RARECAREnet and 46% of the European Union 
population (excluding Norway, Switzerland, and Iceland, which are not EU members) (7). The list 
(http://www.rarecarenet.eu/rarecarenet/index.php/cancerlist) is derived from the data of population-based 
cancer registries from 27 European countries adhering to the RARECAREnet project (8-10). 
Incidence  
With an incidence rate of 16/100,000 corresponding to about 87,000 new EU annual cases, the sum of all 
rare gynaecological tumours (RGT), including ovarian, fallopian tube, uterine, cervical, vaginal, and vulvar 
cancers, represent more than 50% of all gynaecologic malignancies, are  an important challenge for clinicians 
(11).  
Out of the overall RGT diagnosed between 2000-2007, 48% were rare ovarian tumours. Rare eepithelial 
ovarian cancers were the most common entity, with a crude incidence rate of 7.3 per 100,000 going down to 
1.2/100,000 considering the very rare epithelial tumours and excluding the adenocarcinoma of ovary; non 
epithelial ovarian cancers are all rare with an incidence rate of 0.25 per 100,000 (table 1).  
Among rare epithelial tumours of the ovary, 63% were mucinous adenocarcinomas, 25% were clear cell 
adenocarcinomas and 12% MMMT (Mixed mesodermal malignant tumours [now classified as 
Carcinosarcoma]). The incidence increased moderately with age for these cancers, contrary to other frequent 
epithelial ovarian cancers.  
Among sex cord tumours, granulosa cell tumours were the most common histotypes (90% of cases) while  
Sertoli-Leydig cell tumours accounted for 4% of cases; the remaining were few cases of several histotypes 
(thecoma malignant, Sertoli cell or Leydig pure cell tumours NOS, malignant steroid cell tumours). Among 
germ cell tumours, the most common histologies were immature teratomas (42%), followed by 
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dysgerminomas (33%), Yolk sac tumours (15%) and mixed germ cell tumours (4%); the remaining were few 
cases of different histotypes (embryonal carcinoma, polyembryoma, choriocarcinoma combined with other 
germ cell elements, choriocarcinoma, NOS). Germ cell tumours were mostly diagnosed among children and 
young adults, with median age at 27 years (range 1-81) and 36 years (range 2-98) respectively.  Sex cord 
tumours occurred mainly in adulthood (median age was 56 years, range 6-93).  
Survival  
Five-year relative survival (RS) was 54% (95%CI 53.6-55.3) for very rare epithelial tumours of ovary and 82% 
(95%CI 81-84) for non-epithelial ovarian cancers. Among the rare epithelial tumours the carcinosarcomas 
were those with the worse prognosis. A fairly good prognosis was observed for all the histotypes of non-
epithelial tumours of ovary, with germ cell tumours having slightly better prognosis (5-year RS 85%; 95%CI 
83-87) than sex cord tumours (5-year RS 79%; 95% CI 77-81) (Table 3). Survival differences by age and 
histotype were marked in some cases with older patients (<65 years) having always the worse prognosis 
(Table 4). Interestingly, survival data within the European Union varied slightly by region with Eastern Europe 
having generally lower survival than the other areas (Figure 1). Geographic variation in survival for these 
cancers might reflect differences in the use of effective treatment protocols and health care organisation for 
these rare cancers. 
Complete Prevalence 
In the EU in 2008 about 119,000 women were expected to be alive with a past diagnosis of a rare ovarian 
cancer (excluding adenocarcinoma of ovary): 86,000 had a diagnosis of rare epithelial ovarian cancers 
(mucinous adenocarcinoma, clear cell adenocarcinoma, and carcinosarcoma; 31,369 had a diagnosis of non-
epithelial ovarian cancers.  
 
These data derived from the largest available database on rare cancers obtained from European CRs. For rare 
cancers, the most likely quality problem is lack of specificity of morphology codes making it impossible to 
assign such cases to a specific histology. Unspecified morphology can be due to genuine difficulty in assigning 
a specific morphological category or because inadequate documentation was supplied to the CR when the 
case was registered. The latter is registration bias and results in incidence and prevalence underestimation. 
To assess the extent of registration bias, RARECARE reviewed the original data (mainly pathologic reports) of 
a selected sample (about 18,000 cases) of eight rare cancers (Trama A, Tumori Journal). Briefly, the great 
majority of NOS morphology cases were confirmed as NOS. The few NOS cases that changed to a more 
specific diagnosis generally increased the incidence of the more common cancer forms. This finding suggests 
that the problem with poorly specified morphology cases is mainly one of difficulty in reaching a precise 
diagnosis, not registration bias.  
Reaching a correct pathological diagnosis in rare tumours can be challenging, not only because of the rarity 
of a condition, but also because these tumours may have an unusually complex histotypic appearance.  For 
these reasons, the correct diagnosis may be more easily obtained by expert and centralized pathological 
review. A recently published work on central review of rare ovarian tumours reported a modification of the 
diagnosis between 9 to 37% of cases (12;13). Thus, recording data in a rare tumour database alone is not 
sufficient for collecting information on rare tumours. Consideration is needed to ensure accurate recording 
of histopathological data within an expert pathology setting and central pathology review when required. A 
further limitation of the data reported by European registries is that coverage of European areas is not 
homogeneous; more than 50% of the recorded cases were diagnosed in the UK and Nordic countries.  One 
of the key reasons is that national registries are concentrated in these areas, while in Central and Southern 
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Europe registries are mostly locally organized. Furthermore, Eastern Europe is represented by only two 
registries.  
Quality management for rare gynaecologic cancers. 
 
Whilst guidelines are helpful in providing a degree of harmonization of treatment, it is clear that the 
management of rare gynaecological tumours is particularly complex and requires a multi-disciplinary 
approach. Pathologists, radiologists, surgeons, radiation therapists, medical oncologists and paediatric 
oncologists, play a key role in most cases. In some situations an even broader range of support from clinicians 
from other disciplines is needed. Adequate knowledge of these neoplasms is essential for an accurate 
diagnosis, the choice of surgical treatment, adjuvant therapy and effective medical treatment at relapse. This 
can be provided by involving reference centres for gynaecological cancers to centralise diagnosis and care, 
or by the establishment of reference networks that share their multidisciplinary expertise creating an 
environment in which a high volume of patients are treated each year. Such centres are also involved in 
clinical trials, which include a high proportion of patients with gynaecological cancers (14). In France, a 
dedicated rare gynaecologic cancer network has been created to diagnose and manage rare tumours. This 
allows French physicians to seek advice on the diagnosis and surgical and medical management of the 
patients through a dedicated regional or national expert panel of multidisciplinary staff (15). Patients are 
registered through a website that also provides national guidelines, an updated bibliography and information 
for patients and families. Given the rapid success of this experience with patients and physicians, the scientific 
board decided in 2008, with a substantial financial support from the French Cancer Institute (INCa), to 
broaden the scope of the website and offer clinical information and collect biological samples (16). 
However, in the past 5 years there has been an explosion in our understanding of the heterogeneity of 
gynaecological cancers, so a global approach is needed to share information and collect complex biological 
and clinical data for research into the treatment of these rare tumours. Although the management of RGTs 
by oncologists and gynaecologists is now much better organized at a national level, no specific structured 
collaborations exist internationally. Consequently, in 2012 the GCIG (Gynaecologic Cancer Intergroup) an 
organization of national gynaecological cancer trials groups decided to develop a collaborative research 
initiative and clinical trials in ‘moderately rare’ and ‘very rare’ gynaecological cancers (17). The main 
objectives were: 1) to define current recommendations for the management of rare gynaecologic tumours; 
2) to define control arms for present and future clinical trials involving these cancers and to prioritize and 
design international initiatives in rare gynaecologic cancers. The first step for the GCIG was to develop clinical 
management guidelines for the major histological subtypes of rare tumours. To achieve this the major 
national groups formulated a series of documents to harmonize the management of first line and relapsed 
treatment of twenty specific rare gynaecological cancers. (These were published in 2014 in the International 
Journal Gynaecologic Cancer). The next step will be to use these documents to design and develop clinical 
trials in these tumours to improve the outcome of treatment (18). 
 
Dedicated studies design for rare gynaecologic cancers 
 
Establishing surgical trials requires a concentration of committed surgeons and enrolment of a sufficiently 
large group of patients. For novel systemic therapy trials in rare tumours there may not be a clear ‘lead’ 
compound, as these are frequently being sought in more common tumours. However, as our understanding 
of the molecular nature of rare gynaecological cancers grows, and the number of new compounds emerging 
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increase it is important to review which of these agents might also be considered appropriate for trials in 
rare gynaecological tumours. 
Uncommon variants of gynaecologic cancers 
 
It is clear that with a restriction in the number of patients available for trials novel designs are needed to 
explore the activity of a number of potential compounds. Furthermore, access to these novel drugs can be 
difficult; most are developed through the pharmaceutical industry and it can be difficult to persuade industry 
to invest resources to the study of rare tumours. Here, academic leadership is key; firstly for leverage of 
academic funding and secondly to engage with industry. It also requires a commitment from the clinical 
community and local institutions; setting up trials for only a few patients is costly, and enthusiasm to recruit 
only a few patients per year is challenging. This can be helped by establishing referral networks to centralise 
care within clinical trials for these few patients. However, even with the best intentions running randomised 
trials can be problematic. An international trial in mucinous ovarian cancer (mEOC/GOG241), opened in 
multiple sites closed early due to poor recruitment. The reasons ranged from the rarity of the disease(less 
common than predicted with only 47% confirmed on pathological review to have the disease) to difficulties 
in funding chemotherapy drugs that were given out of licence (Gore et al ASCO 2015).  Methods advocated 
for clinical trials in rare diseases are not necessarily applicable in rare cancers, and the choice of method used 
is related to where the cancer lies on a sliding scale of rarity. The approaches that we discussed will enable 
evidence-based clinical practice for rare cancers in the future, particularly in the rapidly developing era of 
molecularly defined cancers. Methods outside the conventional approach might not be ideal, but pragmatic 
solutions have to be sought to enable some level of evidence-based health care in this setting (19). Bayesian 
or adaptive designs or MAMS (multi-arm multistage) trials are options to consider when evaluating multiple 
new agents in a randomized setting (20). New agents can be introduced without stopping and re-starting 
protocols by using a single protocol with subsequent substantial amendments as new drugs are introduced 
(21).  Exploration of methods for the design and analysis of clinical studies of rare diseases continues to be a 
research priority, as evidenced by three projects funded by the European Union within the 7th Framework 
Programme (ASTERIX: FP7 HEALTH 2013–603160; IDEAL: FP7 HEALTH 2013–602552; INSPIRE: FP7 HEALTH 
2013–602144). Such methodological developments could further improve assessments of new treatments in 
rare cancers, reduce the administrative costs of a trial and increase efficiency by avoiding some of the 
regulatory barriers and ultimately improve patient care. 
Very rare tumours 
 
Single arm phase II trials are usually criticized as results may be confounded by selection bias. They continue 
to be performed but interpretation of results can be difficult (22).  To avoid such bias, alternative statistical 
methods such as a randomized Bayesian design (23) can be used. For example, for sex-cord stromal tumours, 
a GCIG randomized trial (Alienor trial) exploring bevacizumab in combination with weekly paclitaxel or 
chemotherapy alone, led by the French Group (GINECO) (NCT01770301) has been launched. By using a 
Bayesian statistical plan, only 60 patients are needed to compare two treatment groups of women with this 
rare tumour. Alternative strategies to a randomized trial include using a historical control group a randomized 
discontinuation design, or using the patient as their own control to compare PFS results with a previous line 
of therapy (24) have all been considered as a means of overcoming the challenge of recruiting an adequate 
number of patients to trials in rare tumours  
However, for very rare tumours it is very unlikely that progress will be made through even single arm phase 
II trials.  Prospective collection of data through national or still better international tumour registries may be 
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the simplest and most cost-effective way forward to learn about rare tumours, harmonize treatments and 
improve outcome through repeated audit of data. Established database repositories can be adapted (e.g. 
http://project-redcap.org), or a customized approach can be developed. The experience of the French 
GINECO group, supported by the National Cancer Institute (INCa) on a national network (http://www.ovaire-
rare.org), including collection of more than 8000 patients provides  important data to improve clinical 
management and research at the national level (25). It is particularly important that in addition to collecting 
clinical data registries also gain access to tumour and blood samples for molecular analysis.  
Clinical databases collecting information on biological characteristics of rare cancers and on their patterns of 
care should also highly contribute to increase the knowledge of these tumours and improve their clinical 
management. 
 
Need for international collaborations 
 
Notwithstanding the difficulties of conducting trials in rare tumours the randomized trial provides the highest 
level of evidence to support a new treatment for gynaecological cancers, and it has been the key approach 
used by regulatory authorities to approve new drugs. Multi-centre national clinical trials, often with 
international collaboration are needed to improve the treatment of even relatively common gynaecological 
cancers. The GCIG, established in 1997 now has a network of 28 national gynaecological cancer trials groups 
that are committed to developing better treatments through international collaboration (26). The value of 
such collaboration is even greater when researching rare tumours.  
An International Rare Cancer Initiative (IRCI) has been established specifically to deal with some of these 
challenges. A consortium established by  Cancer Research UK (CRUK), the National Institute of Health 
Research Clinical Research Network: Cancer (NIHR CRN:Cancer), the National Cancer Institute (NCI), 
the European Organisation for Research and Treatment of Cancer (EORTC), the Institute National Du Cancer 
(INCa) and the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)(27;28). IRCI has now 
approved a randomized trial in advanced high grade undifferentiated uterine sarcoma that will compare 
maintenance carbozantinib with placebo after response to chemotherapy (NCT01979393).  
 
Clinical databases collecting information on biological characteristics of rare cancers and on their patterns of 
care should also highly contribute to increase the knowledge of these tumours and improve their clinical 
management. Genomic dataset of these patients and collaboration with experienced genomic cores will be 
fundamental, even rare cancers may have a different genomic pattern and deserve a different approach. 
Also, the interpretation of clinical studies may benefit from linking response to genomic characteristics. An 
example of this type of databases is the French website (www.ovaire-rare.org) developed to collect clinical 
cases and tumour samples of rare ovarian cancers to define better prognostic factors and to develop specific 
trials. 
 
One way to overcome these challenges, would be to establish centres of expertise for these rare cancers. An 
example of what can be achieved through centralized care of a rare gynaecological malignancy is provided 
by the UK system for managing gestational trophoblastic disease (29). This has played a central role in 
developing new internationally adopted management strategies that have transformed survival rates from 
what used to be a universally lethal outcome to one where nearly all women are cured (30). As a consequence 
of this, other groups across the world are establishing their own centres including Europe, where a network 
(EOTTD.org) has been established. It is now necessary for us to envisage networks of such centres for other 
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rare gynaecological cancers across the EU to thereby achieve the necessary organizational structure and 
critical mass to carry out clinical trials, optimise patient care and improve the biological knowledge of these 
diseases. The European Commission is implementing the Directive 2011/24/EU of the European Parliament 
and the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare. In principle, 
this Directive is meant to grant EU patients the right to access safe and good-quality treatment across EU 
borders. A “by-product” of all this is the creation of the European Reference Networks (ERNs), as a means to 
provide “highly specialised healthcare for rare or low-prevalence complex diseases” (31).The formal 
activation of ERNs in 2017 will be a cornerstone in the EU cooperation on rare cancers. Thus, it was decided 
that the Joint Action on Rare Cancers (JARC) of the European Public Health Programme should be 
instrumental to this (32). In fact, JARC aims to optimise the creation process of the ERNs, by providing them 
with operational solutions and professional guidance in the areas of quality of care, epidemiology, research 
and innovation, education and state of the art definition on prevention, diagnosis and treatment of rare 
cancers. JARC was launched in October 2016 to support cooperation between the Commission and the 
Member States. Coordinated by the Instituto Nazionale dei Tumori of Milan (Italy) JARC takes advantage of 
a strong partnership of 34 partners and 18 European Member States. This is viewed as a great opportunity 
to improve patient care and research in rare cancers within Europe. 
In the course of their work on European Centres of Reference (ECR), a Working Group of medical care and 
health services (comprised of representatives from member states) has decided to seek advice from an 
expert group on Centres of Reference on several specific issues. European Reference Networks (ERNs) for 
rare diseases should serve as research and knowledge centres, updating and contributing to the latest 
scientific findings, treating patients from other Member States and ensuring the availability of subsequent 
treatment facilities where necessary. In 2016, an EU call for rare cancer was set up and several countries 
applied to become an EU network dedicated to rare adult cancers. EURACAN (RAre Adult CANcer) aims to 
establish a world-leading, patient-centric and sustainable network of multidisciplinary research-intensive 
clinical centre focused on rare adult cancers (RAC) with the underlying vision to i) standardize and improve 
the quality of care of all RAC in European adult patients and ii) ensure an optimised access to clinical 
innovation in the field of RAC and across all Member States (MS) (figure 2). With associate partners, in 
particular patients advocacy groups, preparation and dissemination of multilanguage information documents 
on the nature of the disease, treatments, management, reference centers for treatment and appropriate 
contacts within patients advocacy groups as well as patient education and empowerment will be developed. 
Conclusions  
 
National experiences from reference networks have shown that providing information to the primary care 
physicians, and a national coordination of diagnostic procedures facilitates adherence  to clinical practice 
guidelines (6). All these experiences are clearly favourable to the management of rare cancers, and result in 
less delay in treatment that is frequently seen when diagnosis and treatment decisions are made without 
specialised input (6) . High quality management of rare gynaecologic cancers needs to be based on scientific 
evidence that should include, international consensus guidelines, multidisciplinary managed care, and high 
quality clinical trials. The organisation should take account of national and local structures and can be 
facilitated by having reference centres for gynaecological cancers and/or reference networks sharing 
multidisciplinary expertise and access to clinical trials, so that information gathering and sharing of results is 
a coordinated approach to the treatment of a large number of patients each year (33). Patients and patient 
advocacy groups should take part in the development of these European networks! Conducting trials in a 
small number of patients presents its own challenges; novel trial design, overcoming regulatory barriers for 
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international collaboration and funding of studies in rare tumours by academic bodies with little or no 
pharmaceutical support. The survival differences (RERACARE project (34)) by histotype, confirmed that the 
considered rare gynecological cancers, as many other infrequent cancers, present several challenges due to 
their rarity. Their diagnosis requires expertise and centralized review. Their natural history is poorly 
understood and prognostic factors have to be clarified. Many of these difficulties can be overcome through 
the establishment of robust international collaborations that harmonize the approach to clinical trials. 
However, there remain diseases for which clinical trials are virtually impossible to perform. For these we 
need reliable data collection by national registries that can be merged to form international data sets.  
 
 
Table 1. Crude and age adjusted incidence rate (IR per 100,000) of rare ovarian cancers  
by histology with 95% Confidence Intervals (95%CI) in the RARECAREnet database 
 
 
Crude IR  95% CI Age adj IR  95%CI 
Rare epithelial tumours of ovary 1.22 1.20 1.23 1.05 1.04 1.07 
Mucinous adenocarcinoma of ovary 0.77 0.76 0.78 0.67 0.66 0.68 
Clear cell adenocarcinoma of ovary 0.30 0.29 0.31 0.27 0.26 0.28 
Carcinosarcoma of ovary 0.14 0.14 0.15 0.12 0.11 0.12 
Non epithelial tumours of ovary 0.25 0.24 0.26 0.24 0.23 0.25 
Sex cord tumours of ovary 0.12 0.12 0.13 0.11 0.11 0.12 
   Granulosa cell tumours malignant 0.11 0.11 0.12 0.10 0.10 0.10 
   Sertoli Leidig cell tumours 0.00 0.00 0.01 0.00 0.00 0.01 
   Other sex cord tumours of ovary 0.01 0.01 0.01 0.01 0.01 0.01 
Germ cell tumour of ovary 0.13 0.12 0.13 0.13 0.12 0.13 
   Yolk sac tumors 0.02 0.02 0.02 0.02 0.02 0.02 
   Dysgerminoma 0.04 0.04 0.05 0.04 0.04 0.05 
   Mixed germ cell tumors 0.01 0.00 0.01 0.01 0.00 0.01 
   Malignant/Immature teratomas of ovary 0.05 0.05 0.06 0.05 0.05 0.06 
















Table 2. Age specific incidence rate (IR per 100,000) of rare ovarian cancers by histology with 95% Confidence Intervals (95%CI)  in the RARECAREnet database 
 
  00-14 years 15-24 years 25-64 years 65 +  years 
  IR  95%CI IR 95%CI IR 95%CI IR 95%CI 
Rare epithelial tumours of ovary 0.001 0.000 0.003 0.118 0.104 0.134 1.312 1.288 1.337 3.055 2.986 3.124 
Mucinous adenocarcinoma of ovary 0.001 0.000 0.003 0.113 0.099 0.129 0.837 0.818 0.857 1.879 1.825 1.933 
Clear cell adenocarcinoma of ovary NA NA NA 0.004 0.002 0.008 0.369 0.356 0.382 0.640 0.609 0.672 
Mullerian mixed tumour of ovary NA NA NA 0.001 0.000 0.004 0.107 0.100 0.114 0.536 0.508 0.565 
Non epithelial tumours of ovary 0.114 0.101 0.128 0.331 0.306 0.357 0.257 0.246 0.268 0.302 0.281 0.324 
Sex cord tumours of ovary 0.004 0.002 0.008 0.026 0.019 0.034 0.150 0.142 0.159 0.240 0.221 0.260 
   Granulosa cell tumours malignant 0.003 0.001 0.006 0.017 0.012 0.024 0.137 0.129 0.145 0.214 0.197 0.233 
   Sertoli Leidig cell tumours 0.001 0.000 0.003 0.005 0.003 0.010 0.005 0.004 0.007 0.006 0.004 0.010 
   Other sex cord tumours of ovary 0.000 0.000 0.001 0.003 0.001 0.006 0.008 0.007 0.011 0.019 0.014 0.025 
Germ cell tumour of ovary 0.110 0.097 0.123 0.305 0.281 0.330 0.107 0.100 0.114 0.062 0.053 0.073 
   Yolk sac tumors 0.019 0.014 0.026 0.050 0.041 0.061 0.017 0.014 0.020 0.004 0.002 0.007 
   Dysgerminoma 0.039 0.032 0.047 0.144 0.128 0.161 0.028 0.025 0.032 0.009 0.006 0.013 
   Mixed germ cell tumors 0.008 0.005 0.012 0.016 0.011 0.022 0.003 0.002 0.005 0.001 0.000 0.003 
   Malignant/Immature teratomas of ovary 0.039 0.032 0.047 0.087 0.074 0.101 0.051 0.047 0.056 0.047 0.039 0.056 
   Other germ cell tumours of ovary 0.005 0.002 0.008 0.008 0.005 0.013 0.007 0.005 0.009 0.002 0.001 0.005 
 
   
NE: not estimable because no cases were observed in the period (2000-2007)   
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Table 3. Number of cases on which the analyses are based, 5-year relative survival (RS%) of rare  
ovarian cancers by histology with 95% Confidence Intervals (95%CI)  in the RARECAREnet database 
 N 5-year RS (%) 95% CI 
Rare epithelial tumours of ovary 19,009 54 53.59 55.25 
Mucinous adenocarcinoma of ovary 12,010 60 58.84 60.88 
Clear cell adenocarcinoma of ovary 4,761 55 53.78 57.17 
Mullerian mixed tumour of ovary 2,242 21 19.41 23.49 
Non epithelial tumours of ovary 3,906 82 80.82 83.71 
Sex cord tumours of ovary 1,937 79 76.86 81.49 
   Granulosa cell tumours malignant 1,741 80 77.73 82.57 
   Sertoli Leidig cell tumours 74 68 54.55 78.96 
   Other sex cord tumours of ovary 122 72 60.12 80.38 
Germ cell tumour of ovary 1,969 85 83.38 86.85 
   Yolk sac tumors 302 86 81.30 89.78 
   Dysgerminoma 659 90 87.64 92.62 
   Mixed germ cell tumors 85 85 74.03 91.31 
   Malignant/Immature teratomas of ovary 829 83 80.35 86.02 
   Other germ cell tumours of ovary 94 63 50.77 72.53 
 





Table 4. Number of cases on which the analyses are based, 5-year relative survival (RS%) of rare ovarian cancers by histology with 95% Confidence Intervals (95%CI)  
in the RARECAREnet database 
 
NE: not estimable because no cases were observed in the period (2000-2007) 
 
  
00-14 years 15-24 years 25-64 years 65 +  years 
N RS 95%CI N RS 95%CI N RS 95%CI N RS 95%CI 
Rare epithelial tumours of ovary 2 50.04% 0.59% 91.07% 238 87.31% 82.15% 91.06% 11,166 61.75% 60.74% 62.74% 7,603 41.98% 40.57% 43.39% 
Mucinous adenocarcinoma of ovary 2 50.04% 0.59% 91.07% 227 88.05% 82.83% 91.76% 7,114 67.74% 66.53% 68.91% 4,667 45.73% 43.89% 47.55% 
Clear cell adenocarcinoma of ovary 0 NE NE NE 8 74.19% 29.61% 92.94% 3,150 57.63% 55.62% 59.59% 1,603 51.05% 47.80% 54.20% 
Mullerian mixed tumour of ovary 0 NE NE NE 3 66.77% 5.35% 94.58% 904 26.93% 23.65% 30.32% 1,335 17.45% 14.97% 20.08% 
Non epithelial tumours of ovary 298 94.95% 91.34% 97.08% 666 91.80% 89.23% 93.77% 2,192 83.91% 82.06% 85.57% 750 63.28% 58.29% 67.85% 
Sex cord tumours of ovary 11 78.03% 35.35% 94.25% 52 68.34% 52.73% 79.74% 1,280 83.87% 81.32% 86.10% 594 70.14% 64.44% 75.11% 
   Granulosa cell tumours malignant 8 71.71% 25.17% 92.30% 35 64.93% 45.26% 79.04% 1,165 84.76% 82.12% 87.05% 533 71.29% 65.24% 76.48% 
   Sertoli Leidig cell tumours 3 NE NE NE 11 71.86% 35.46% 90.00% 44 73.96% 55.21% 85.80% 16 48.20% 20.55% 71.41% 
   Other sec cord tumours of ovary 0 NE NE NE 6 83.44% 27.06% 97.53% 71 75.12% 61.34% 84.58% 45 64.85% 41.14% 80.96% 
Germ cell tumour of ovary 287 95.60% 92.06% 97.58% 614 93.76% 91.30% 95.54% 912 83.92% 81.17% 86.31% 156 36.60% 26.87% 46.37% 
   Yolk sac tumors 51 96.03% 84.49% 99.03% 101 91.80% 84.08% 95.87% 141 83.43% 75.83% 88.82% 9 NE NE NE 
   Dysgerminoma 101 100.08% NE NE 290 95.85% 92.43% 97.74% 244 85.56% 79.98% 89.68% 24 29.97% 10.09% 53.09% 
   Mixed germ cell tumors 21 90.15% 65.73% 97.47% 32 85.96% 65.83% 94.68% 30 81.69% 59.59% 92.40% 2 NE NE NE 
   Malignant/Immature teratomas of 
ovary 102 96.34% 88.63% 98.86% 175 94.70% 89.87% 97.26% 436 86.28% 82.40% 89.35% 116 41.99% 30.39% 53.14% 







Figure 2. EURACAN targeted rare adult cancer (The governance) 
 
 
Figure 1, Five-year Relative Survival for rare epithelial and non epithelial ovarian cancer with 95% Confidence  
Intervals by European area 
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